Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 6 de 6
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Immun Inflamm Dis ; 12(3): e1219, 2024 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-38501534

RESUMO

INTRODUCTION: Down syndrome (DS) is associated with multiple comorbid conditions and chronic immune dysfunction. Persons with DS who contract COVID-19 are at high risk for complications and have a poor prognosis. We aimed to study the clinical symptoms, laboratory and biochemical profiles, radiologic findings, treatment, and outcomes of patients with DS and COVID-19. METHOD: We systematically searched PubMed, MEDLINE, Web of Science, Scopus, and the Cochrane Library using the keywords COVID-19 or coronavirus or SARS-CoV-2 and DS or trisomy 21. Seventeen articles were identified: eight case reports and nine case series published from December 2019 through March 2022, with a total of 55 cases. RESULTS: Patients averaged 24.8 years (26 days to 60 years); 29 of the patients were male. The most common symptoms were fever, dyspnea, and cough. Gastrointestinal and upper respiratory tract symptoms were commonly reported for pediatric patients. The most common comorbidities present in patients with DS were obesity (49.0%), hypothyroidism (21.6%) and obstructive sleep apnea (15.6%). The patients were hospitalized for a mean of 14.8 days. When the patients were compared with the general COVID-19 population, the mean number of hospitalized days was higher. Most patients had leukopenia, lymphopenia, and elevated inflammatory markers (d-dimer and C-reactive protein). Bilateral infiltrations and bilateral ground-glass opacifications were frequently seen in chest radiographs and chest computed tomographic imaging. Most of the patients were treated with methylprednisolone, macrolides, and hydroxychloroquine. Of the 55 patients, 22 died. The mean age of the patients who died was 42.8 years. Mortality rate was higher in individuals with DS over 40 years of age. CONCLUSION: More studies are needed to better understand COVID-19 infections among persons with DS. In addition, the study was limited by a lack of statistical analyses and a specific comparison group.


Assuntos
COVID-19 , Síndrome de Down , Linfopenia , Adulto , Criança , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Tosse/epidemiologia , Síndrome de Down/complicações , Síndrome de Down/epidemiologia , SARS-CoV-2 , Recém-Nascido , Lactente , Pré-Escolar , Adolescente , Adulto Jovem
2.
Cardiol Rev ; 2023 Mar 13.
Artigo em Inglês | MEDLINE | ID: mdl-36912509

RESUMO

Cardiac pacing refers to the implantation tool serving as a treatment modality for various indications, the most common of which is symptomatic bradyarrhythmia. Left bundle branch pacing has been noted in the literature to be safer than biventricular pacing or His-bundle pacing in patients with left bundle branch block (LBBB) and heart failure, thereby becoming the focus of further research on cardiac pacing. A review of the literature was conducted using a combination of keywords, including "Left Bundle Branch Block," "Procedural techniques," "Left Bundle Capture," and "Complications." The following factors have been investigated as key criteria for direct capture: paced QRS morphology, peak left ventricular activation time, left bundle potential, nonselective and selective left bundle capture, and programmed deep septal stimulation protocol. In addition, complications of LBBP, inclusive of septal perforation, thromboembolism, right bundle branch injury, septal artery injury, lead dislodgement, lead fracture, and lead extraction, have also been elaborated on. Despite clinical implications based on clinical research comparing the use of LBBP with other forms such as right ventricular apex pacing, His-bundle pacing, biventricular pacing, and left ventricular septal pacing, a paucity in the literature on long-term effects and efficacy has been noted. LBBP can thus be considered to have a promising future in patients requiring cardiac pacing, assuming that additional research on clinical outcomes and the limitation of significant complications such as thromboembolism can be established.

3.
Curr Heart Fail Rep ; 20(1): 44-55, 2023 02.
Artigo em Inglês | MEDLINE | ID: mdl-36692820

RESUMO

PURPOSE OF REVIEW: As the percentage of patients achieving long-term survival following treatment of their cancer grows, it is increasingly important to understand the long-term toxicities of cancer-directed treatment. In this review, we highlight the recent findings regarding radiation-induced cardiotoxicity across multiple disease sites, with a particular focus on heart failure. RECENT FINDINGS: Despite its relative lack of study historically, radiation-induced heart failure has now recently been implicated in several studies of breast cancer, lung cancer, esophageal cancer, and lymphoma as a non-trivial potential consequence of thoracic radiotherapy. Data regarding specific cardiac dosimetric endpoints relevant to cardiotoxicity continue to accumulate. Radiation-induced heart failure is a rare but significant toxicity of thoracic radiotherapy, that is likely underreported. Important areas for future focus include understanding the interplay between thoracic radiotherapy and concurrent cardiotoxic systemic therapy as well as development of potential mitigation strategies and novel therapeutics.


Assuntos
Neoplasias da Mama , Cardiopatias , Insuficiência Cardíaca , Humanos , Feminino , Cardiotoxicidade , Coração
4.
Cureus ; 13(11): e19791, 2021 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-34956783

RESUMO

BACKGROUND: In coronavirus disease 2019 (COVID-19) patients, risk stratification based on clinical presentation, co-morbid illness, and combined laboratory parameters is essential to provide an adequate, timely intervention based on an individual's conditions to prevent mortality among cases. METHODS: A retrospective observational study was carried out from June to October 2020, including all reverse transcription-polymerase chain reaction (RT-PCR) positive COVID-19 non-survivors and control group survivors randomly selected after age and sex matching. Clinical and demographic information was collected from the medical records. Categorical variables were expressed by frequency and percentage. To explore the risk factors associated with mortality, univariable and multivariable logistic regression models were used. RESULTS AND DISCUSSIONS: All non-survivors (n = 100) and 100 survivors (out of 1,018) were analyzed. Male gender (67.4%) was the independent risk factor for COVID-19 infection. Advanced age group, diabetes, cardiovascular, neurological, and hypertensive co-morbidities were statistically associated with mortality. Cardiac arrest and acute kidney injury (AKI) were the most common complications. Mortality is significantly associated with lymphopenia and raised lactate dehydrogenase (LDH), as shown by higher odds. In addition, raised neutrophils, monocytes, aspartate aminotransferase (AST), serum creatinine, interleukin 6 (IL-6), and C-reactive protein (CRP) are also significantly associated with mortality. The most common causes of death were respiratory failure (84%) and acute respiratory distress syndrome (77%). Of the non-survivors, 92% received corticosteroids, 63% were on high-flow nasal cannula oxygen therapy, 29% were mechanically ventilated, and 29% received tocilizumab. CONCLUSION: Serial monitoring of neutrophils, lymphocytes, D-dimer, procalcitonin, AST, LDH, CRP, IL-6, serum creatinine, and albumin might provide a reliable and convenient method for classifying and predicting the severity and outcomes of patients with COVID-19.

6.
Cureus ; 12(9): e10488, 2020 Sep 16.
Artigo em Inglês | MEDLINE | ID: mdl-33083188

RESUMO

Background Arrhythmias are one of the reasons for emergency hospitalization among the pediatric population. Radiofrequency ablation is a major advancement in the management of children with cardiac arrhythmias. Objectives Our study was designed to describe the outcomes of catheter ablation in the pediatric population for atrial and ventricular arrhythmias in our center. Methods All patients between two and 18 years of age undergoing radiofrequency ablation after failed medical management for arrhythmias in our institute were included. Age less than two years, no previous medical management, and complex congenital heart disease were excluded. Baseline and electrophysiological characteristics were recorded. The patients were followed up for a clinical or electrocardiographic recurrence of arrhythmia. Results Thirty-six patients were included (mean age 12.8 ± 3.9 years (range 2-18 years), male 56%, average weight 36.39 ± 11.02 kg). The mean follow-up duration was 27.7 ± 15.9 months (range 3-58). Five-point five percent (5.5%) had tachycardiomyopathy. The arrhythmias included (1) atrioventricular nodal re-entrant tachycardia (AVNRT, n=16, 44%), (2) atrioventricular reciprocating tachycardia (AVRT, n=14, 39%), (3) atrial tachycardia (AT, n=2, 5.5%), (4) ventricular premature complexes (VPCs, n=2, 5.5%), (5) atrial flutter (AFL, n=1, 3%), and (6) ventricular tachycardia (VT, n=1, 3%). A transeptal puncture was done in 10 patients (28%). 3D mapping was done in six patients. The mean radiofrequency (RF) pulses were 2.3 ± 1.3. The acute procedural success rate was 100%. The long-term success was 97.2%. One (2.7%) developed recurrence. No major complications were reported. Conclusion Catheter ablation in the pediatric population is a safe procedure and can be done with more feasibility and fewer complications when done in experienced hands.

SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...